Latest issue New England Medical Journal Reports promising results in treating Alzheimer’s disease using focused ultrasound technology that disrupts the blood-brain barrier
- Focused ultrasound temporarily opens the blood-brain barrier and enhances drug delivery
- Study finds that combined approach of focused ultrasound and monoclonal antibody delivery can promote reduction of beta-amyloid plaques, a hallmark of Alzheimer’s disease
- Alzheimer’s disease currently affects 6.7 million Americans
haifa, israel and miami, January 4, 2024 /PRNewswire/ — InsightecThe company, a global healthcare company dedicated to transforming patient care using acoustic energy, today announced promising clinical research in the treatment of Alzheimer’s disease utilizing focused ultrasound (FUS) technology. . This study is reported in the current issue. of New England Medical Journal.
This research WVU Rockefeller Neuroscience Institute (RNI), offers reassuring benefits for Alzheimer’s patients. RNI researchers are collaborating with Insightec to combine the use of focused ultrasound to open the blood-brain barrier with the delivery of systemic infusions of monoclonal antibodies to enhance clearance of brain beta-amyloid, a hallmark of Alzheimer’s disease. succeeded in. This innovative therapeutic approach has shown promise in enhancing targeted drug delivery in Alzheimer’s disease and other neurological conditions.
“Focused ultrasound provides new opportunities for Insightec and pharmaceutical company collaboration to improve drug delivery to the brain.” Dr. Maurice R. Ferret, CEO and Chairman of the Board of Insightec. “Only 1-2% of drugs can cross the blood-brain barrier, so using high systemic drug concentrations makes progression difficult and patient safety difficult. Being able to effectively deliver treatment demonstrates the ability and potential of disrupting the blood-brain barrier through focused ultrasound technology when dealing with complex neurological conditions.”
“The results of this proof-of-concept study are encouraging and point the way to improved drug delivery to combat Alzheimer’s disease,” he said. Ali Rezai,medical doctor, Executive Chairman of RNI. “Our longstanding close collaboration with Insightec will accelerate advances in the treatment of patients with Alzheimer’s disease and other neurological diseases.”
Alzheimer’s disease currently affects 6.7 million Americans, and promising new treatments are emerging to address this unmet medical need. This latest breakthrough opens new avenues for research and brings new hope to patients and their loved ones. As research progresses, this therapeutic approach is expected to evolve and be refined, paving the way for even more effective treatments.
Manufacturers of ultrasound equipment (Insightec, Tirat Carmel, Israel) or the manufacturer of aducanumab (Biogen, Cambridge, united states of america -) Sponsored the study or participated in any way in study design, data collection, analysis, interpretation, or manuscript writing.
For more information on the study, click here.
About Insightec
Insightec is a global healthcare company building the next generation of patient care by realizing the therapeutic power of acoustic energy. The company’s Exablate Neuro platform focuses sound waves while safely guided by MRI to deliver tremor therapy to patients with drug-resistant essential tremor and Parkinson’s disease. Research for future applications in the field of neuroscience is underway in partnership with leading academic and medical institutions. Insightec is headquartered in Haifa, Israel, and Miami, with offices in Dallas, Shanghai, and Tokyo.
regarding west virginia university Rockefeller Neuroscience Institute
The WVU Rockefeller Neuroscience Institute (RNI) is a world-class, interdisciplinary patient care, education, and research institution with 250 faculty members and more than 1,500 experts across five departments serving 275,000 patients annually. We provide neurological and mental health care. RNI improves lives through pioneering advances in brain health and treatment. The RNI team leverages cutting-edge technology, leveraging partnerships between academia and industry, to make measurable progress in combating public health challenges from addiction to Alzheimer’s disease. For more information about WVU Rockefeller Neuroscience Institute, visit WVUMedicine.org/RNI.
For more information, follow us on Facebook, LinkedIn, Twitter or visit www.insightec.com.
Forward-looking statements:
This document contains forward-looking statements regarding, among other things, plans, expectations and future events. In some cases, forward-looking statements include words such as “may”, “could”, “will”, “could”, “will”, “should”, “expect”, “intend”, ” It may be identified by the word ‘to plan’. , “anticipate,” “believe,” “estimate,” “predict,” “plan,” “potential,” “commit,” “continue,” “in progress,” or Negative form of the term. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that may cause actual results to differ materially from those expressed or implied by the statements. Masu. Forward-looking statements are based on information available to Insightec as of the date of such statements. All written or oral forward-looking statements attributable to Insightec are subject to this cautionary statement. Insightec undertakes no obligation to update or revise any forward-looking statements to reflect changed circumstances or Insightec’s expectations.
“Exablate” and “Exablate Neuro” and the “INSIGHTEC” logo, either alone or in conjunction with the word “Insightec”, are protected trademarks of Insightec.
Insightec Media Contact:
G&S Business Communications for Insightec
Emily Decamiris
edecamillis@gscommunications.com
1-919-417-3253
Logo – https://mma.prnewswire.com/media/1699588/4172473/Insightec_Logo.jpg
Source Insight Tech
